Year |
Citation |
Score |
2020 |
Jones LE, Hilz S, Grimmer MR, Mazor T, Najac C, Mukherjee J, McKinney A, Chow T, Pieper RO, Ronen SM, Chang SM, Phillips JJ, Costello JF. Patient-derived cells from recurrent tumors that model the evolution of -mutant glioma. Neuro-Oncology Advances. 2: vdaa088. PMID 32904945 DOI: 10.1093/noajnl/vdaa088 |
0.375 |
|
2020 |
Oberheim Bush NA, Yu Y, Villanueva-Meyer J, Grimmer M, Hilz S, Solomon D, Choi S, Mazor T, Hong C, Shai A, Phillips JJ, McDermott M, Haas-Kogan DA, Taylor J, Butowski NA, et al. Temozolomide-induced hypermutation is associated with high-grade transformation, distant recurrence, and reduced survival after transformation in initially low-grade IDH-mutant diffuse gliomas. Journal of Clinical Oncology. 38: 2506-2506. DOI: 10.1200/Jco.2020.38.15_Suppl.2506 |
0.376 |
|
2020 |
Yu Y, Villanueva-Meyer J, Chang S, Grimmer M, Hilz S, Solomon D, Choi S, Wahl M, Mazor T, Hong C, Shai A, Phillips J, McDermott M, Haas-Kogan D, Taylor J, et al. PATH-12. TEMOZOLOMIDE-INDUCED HYPERMUTATION IS ASSOCIATED WITH HIGH-GRADE TRANSFORMATION, DISTANT RECURRENCE AND REDUCED SURVIVAL IN INITIALLY LOW GRADE IDH-MUTANT GLIOMAS Neuro-Oncology. 22: ii166-ii166. DOI: 10.1093/neuonc/noaa215.694 |
0.328 |
|
2019 |
Zhang M, Hilz S, Martin M, Hong C, Yu Y, Bollam S, Grimmer M, Looney T, Lowman G, Ganpule G, Phillips J, Shai A, Chang S, Clarke J, Taylor J, et al. IMMU-11. SPATIOTEMPORAL IMMUNOGENOMIC ANALYSIS OF THE T-CELL REPERTOIRE IN IDH-MUTANT LOWER GRADE GLIOMAS Neuro-Oncology. 21: vi121-vi121. DOI: 10.1093/Neuonc/Noz175.505 |
0.362 |
|
2019 |
Mathur R, Zhang Y, Grimmer M, Hong C, Berger M, Molinaro A, Ann Oberheim-Bush N, Chang S, Costello J. GENE-35. MGMT PROMOTER METHYLATION IN NEWLY DIAGNOSED LGG AS A POTENTIAL BIOMARKER FOR TMZ-ASSOCIATED HYPERMUTATION AT RECURRENCE Neuro-Oncology. 21: vi105-vi105. DOI: 10.1093/Neuonc/Noz175.437 |
0.41 |
|
2018 |
Choi S, Yu Y, Grimmer MR, Wahl M, Chang SM, Costello JF. Temozolomide-associated Hypermutation in Gliomas. Neuro-Oncology. PMID 29452419 DOI: 10.1093/Neuonc/Noy016 |
0.317 |
|
2018 |
Grimmer MR. Abstract LB-376: Clinico-genomic analysis of temozolomide-induced hypermutation in both molecular subtypes of IDH-mutant glioma Cancer Research. 78. DOI: 10.1158/1538-7445.Am2018-Lb-376 |
0.438 |
|
2018 |
Yu Y, Hilz S, Grimmer M, Solomon D, Choi S, Wahl M, Mazor T, Hong C, Shai A, J Phillips J, Villanueva-Meyer J, McDermott M, Haas-Kogan D, Taylor J, Butowski N, et al. PATH-29. CLINICAL SIGNIFICANCE OF TEMOZOLOMIDE-INDUCED SOMATIC HYPERMUTATION IN INITIALLY LOW-GRADE IDH-MUTANT DIFFUSE GLIOMAS Neuro-Oncology. 20: vi164-vi165. DOI: 10.1093/Neuonc/Noy148.685 |
0.305 |
|
2017 |
Campbell BB, Light N, Fabrizio D, Zatzman M, Fuligni F, de Borja R, Davidson S, Edwards M, Elvin JA, Hodel KP, Zahurancik WJ, Suo Z, Lipman T, Wimmer K, Kratz CP, ... ... Grimmer MR, et al. Comprehensive Analysis of Hypermutation in Human Cancer. Cell. PMID 29056344 DOI: 10.1016/J.Cell.2017.09.048 |
0.336 |
|
2015 |
Cage TA, Chanthery Y, Chesler L, Grimmer M, Knight Z, Shokat K, Weiss WA, Gustafson WC. Downregulation of MYCN through PI3K Inhibition in Mouse Models of Pediatric Neural Cancer. Frontiers in Oncology. 5: 111. PMID 26029667 DOI: 10.3389/Fonc.2015.00111 |
0.54 |
|
2015 |
Cage TA, Chanthery Y, Chesler L, Grimmer M, Knight Z, Shokat K, Weiss WA, Gustafson WC. Downregulation of MYCN through PI3K inhibition in mouse models of pediatric neural cancer Frontiers in Oncology. 5. DOI: 10.3389/fonc.2015.00111 |
0.445 |
|
2015 |
Mazor T, Johnson BE, Grimmer M, Hong C, Hamilton EG, Jones LE, Xavier-Magalhães A, Smirnov IV, Bengtsson H, Olshen AB, Petrecca K, Bollen AW, Berger MS, Taylor BS, Nelson SJ, et al. GENO-25HYPERMUTATION AND MALIGNANT PROGRESSION IN AN EXPANDED COHORT OF TEMOZOLOMIDE-TREATED LOW-GRADE GLIOMA PATIENTS Neuro-Oncology. 17: v97.1-v97. DOI: 10.1093/Neuonc/Nov215.25 |
0.432 |
|
2012 |
Swartling FJ, Savov V, Persson AI, Chen J, Hackett CS, Northcott PA, Grimmer MR, Lau J, Chesler L, Perry A, Phillips JJ, Taylor MD, Weiss WA. Distinct neural stem cell populations give rise to disparate brain tumors in response to N-MYC. Cancer Cell. 21: 601-13. PMID 22624711 DOI: 10.1016/J.Ccr.2012.04.012 |
0.553 |
|
2012 |
Chanthery YH, Gustafson WC, Itsara M, Persson A, Hackett CS, Grimmer M, Charron E, Yakovenko S, Kim G, Matthay KK, Weiss WA. Paracrine signaling through MYCN enhances tumor-vascular interactions in neuroblastoma. Science Translational Medicine. 4: 115ra3. PMID 22218692 DOI: 10.1126/scitranslmed.3002977 |
0.585 |
|
2011 |
Swartling FJ, Persson AI, Lau J, Northcott PA, Grimmer MR, Chesler L, Perry A, Phillips JJ, Taylor MD, Weiss WA. Abstract 3451: Interactions between N-myc and Sox9 promote medulloblastoma and determine cell fate decisions in cerebellar neural stem cells Cancer Research. 71: 3451-3451. DOI: 10.1158/1538-7445.Am2011-3451 |
0.552 |
|
2010 |
Swartling FJ, Grimmer MR, Hackett CS, Northcott PA, Fan QW, Goldenberg DD, Lau J, Masic S, Nguyen K, Yakovenko S, Zhe XN, Gilmer HC, Collins R, Nagaoka M, Phillips JJ, et al. Pleiotropic role for MYCN in medulloblastoma. Genes & Development. 24: 1059-72. PMID 20478998 DOI: 10.1101/Gad.1907510 |
0.584 |
|
2008 |
Chesler L, Goldenberg DD, Collins R, Grimmer M, Kim GE, Tihan T, Nguyen K, Yakovenko S, Matthay KK, Weiss WA. Chemotherapy-induced apoptosis in a transgenic model of neuroblastoma proceeds through p53 induction. Neoplasia (New York, N.Y.). 10: 1268-74. PMID 18953436 DOI: 10.1593/Neo.08778 |
0.571 |
|
2008 |
Grimmer MR, Weiss WA. BMPs oppose Math1 in cerebellar development and in medulloblastoma. Genes & Development. 22: 693-9. PMID 18347086 DOI: 10.1101/Gad.1657808 |
0.52 |
|
2007 |
Chesler L, Goldenberg DD, Seales IT, Satchi-Fainaro R, Grimmer M, Collins R, Struett C, Nguyen KN, Kim G, Tihan T, Bao Y, Brekken RA, Bergers G, Folkman J, Weiss WA. Malignant progression and blockade of angiogenesis in a murine transgenic model of neuroblastoma. Cancer Research. 67: 9435-42. PMID 17909053 DOI: 10.1158/0008-5472.Can-07-1316 |
0.596 |
|
2006 |
Grimmer MR, Weiss WA. Childhood tumors of the nervous system as disorders of normal development. Current Opinion in Pediatrics. 18: 634-8. PMID 17099362 DOI: 10.1097/Mop.0B013E32801080Fe |
0.54 |
|
Show low-probability matches. |